OmegAD study: a randomized double-blind trial.
Freund-Levi Y et al.
Archives of Neurology. 2006;63:1402-8.
Six months' administration of omega-3 fatty acid significantly reduced the Mini-Mental State Examination (MMSE) decline rate in patients with very mild cognitive dysfunction (MMSE >27 points) compared with placebo recipients (p<0.05).
Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction.
Kotani S et al.
Neuroscience Research. 2006;56:159-64.
After 90 days' supplementation of 240 mg/day of arachidonic acid (ARA) and docosahexaenoic acid (DHA), patients with mild cognitive dysfunction experienced a significant improvement in immediate memory and attention score. In addition, patients with organic brain lesions showed a significant improvement in immediate and delayed memories.
Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study.
Schaefer EJ et al.
Archives of Neurology. 2006;63:1545-50.
Over a 9-year study period following 899 study subjects who were participating in the Framingham Heart Study, 99 subjects developed dementia, including 71 cases of Alzheimer's disease (AD). After subjects were divided into quartiles according to their plasma phosphatidylcholine (PC) fatty acid content, those in the upper quartile had a significantly lower risk of developing dementia and AD compared with participants with levels in the lower 3 quartiles. Furthermore, of the study participants who completed a dietary questionnaire, those in the top quartile reported consuming an average of 0.18 g of docosahexaenoic acid (DHA) per day and an average of 3 servings of fish per week.
After 90 days' supplementation of 240 mg/day of arachidonic acid (ARA) and docosahexaenoic acid (DHA), patients with mild cognitive dysfunction experienced a significant improvement in immediate memory and attention score. In addition, patients with organic brain lesions showed a significant improvement in immediate and delayed memories.
Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study.
Schaefer EJ et al.
Archives of Neurology. 2006;63:1545-50.
Over a 9-year study period following 899 study subjects who were participating in the Framingham Heart Study, 99 subjects developed dementia, including 71 cases of Alzheimer's disease (AD). After subjects were divided into quartiles according to their plasma phosphatidylcholine (PC) fatty acid content, those in the upper quartile had a significantly lower risk of developing dementia and AD compared with participants with levels in the lower 3 quartiles. Furthermore, of the study participants who completed a dietary questionnaire, those in the top quartile reported consuming an average of 0.18 g of docosahexaenoic acid (DHA) per day and an average of 3 servings of fish per week.
No comments:
Post a Comment